Corporate Snapshot

Prolor Biotech (formerly Modigene Inc.) is a publicly traded biopharmaceutical company utilizing patented technology to develop longer-lasting, proprietary versions of therapeutic proteins that require injections at high frequencies. The Company focuses on approved proteins with established safety and efficacy records, targeting a therapeutic protein market that is driven by heavy demand and rapid sales in both the U.S. and Europe, with approximately $53 billion in sales in 2005. The Company's technology was discovered by researchers at Washington University ("WashU") in St. Louis, Missouri, and is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in the human body, and when attached to a therapeutic protein, extends the time that such protein can last effectively in the body. This has been demonstrated and validated by Organon International Inc. (the human healthcare business unit of Akzo Nobel N.V. [AKZOY-NASDAQ]). Organon also licenses the CTP technology from WashU, and has attached the CTP to a Follicle-Stimulating Hormone (FSH)—a hormone with approximately $1 billion in annual sales that is prescribed for females undergoing fertility treatments. Via Organon, CTP technology is in Phase III clinical trials. Prolor has an exclusive license with WashU for use of the CTP with all proteins other than four endocrine proteins, which are licensed to Organon.

* The Corporate Snapshot was last updated on August 21, 2007.

Latest Research

Executive
Informational
Overview

2007-08-21

Click to View

Stock Information (PBTH-NYSE Amex)